With new biotech IPOs on the way, here’s a look at the Bay Area companies that filed so far this year

From blank checks to already-acquired companies, and from cancer to rare diseases, the Bay Area life sciences IPO class of 2020 is largely trading above their initial offering prices. Can you see what they have in common?

Click to view original post